JPRN-UMIN000001373
Completed
未知
A Randomized, Double Blind, Comparative Study Of STATUS D3Ⓡ (vitamin D3) Versus Placebo In Children Aged Between 7 And 15 Years Old to prevent infectious diseases including influenza and to improve atopic dermatitis - Preventive Effects of Vitamin D on Infectious Diseases and Allergic conditions Trials for Children Study: PEDIATRICS
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- elementary shool, junior high school children
- Sponsor
- Jikei University School of Medicine
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.already taking vitamin D3 or active form of vitamin D 2\.past history of urethral stone, or having underlying diseases related with calcium and/or bone metabolism 3\.known allergy to sesame, gelatin, d\-solvitor, 4\.difficulty in swallowing capsules for 4 months 5\.during or within 1 year after chemotherapy or immunocompromised conditions 6\.known to move during study period 7\.other reasons that doctor judges impossible to attend the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002940-26-NLJanssen-Cilag International NV1,270
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002940-26-PTJanssen-Cilag International NV1,270
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002940-26-DKJanssen-Cilag International NV1,270
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002940-26-FIJanssen-Cilag International NV1,270
Active, not recruiting
Phase 1
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002940-26-BEJanssen-Cilag International NV1,270